MUSE Stem Cells:
The Future of Regenerative Medicine
Multilineage-differentiating Stress-Enduring cells combine pluripotent regenerative power with an exceptional safety profile — backed by 85+ peer-reviewed studies and multiple Phase II clinical trials.
In This Guide
MUSE cells — short for Multilineage-differentiating Stress-Enduring cells — are a distinct population of adult-derived stem cells that exist naturally in the human body. Discovered in 2010 by Professor Mari Dezawa at Tohoku University in Japan, they represent a breakthrough that the field of regenerative medicine has been pursuing for over three decades.
What makes them remarkable isn’t one thing — it’s the combination. MUSE cells are naturally pluripotent, meaning they can differentiate into cell types from all three embryonic germ layers without any genetic reprogramming. And unlike embryonic stem cells or iPSCs that share this ability, MUSE cells do not form tumors.
What Are MUSE Cells?
MUSE cells are naturally pluripotent, meaning they can differentiate into cell types from all three embryonic germ layers — ectoderm, mesoderm, and endoderm — without any genetic reprogramming or chemical induction. They do this on their own, in the living body, in response to tissue damage.
That combination — pluripotent-like regenerative capacity plus a verified safety profile — is what sets MUSE cells apart from every other stem cell type in regenerative medicine today.
MUSE cells are identified by their expression of SSEA-3 (Stage-Specific Embryonic Antigen-3), a surface marker associated with pluripotent capability. They also express CD105, a mesenchymal stem cell marker. This dual-positive identification (SSEA-3⁺/CD105⁺) distinguishes them from ordinary MSCs, which do not express SSEA-3.
Key Insight: MUSE cells express pluripotency genes (Sox2, Nanog, Oct3/4) while maintaining low telomerase activity and downregulated Lin28 — suppressing oncogenic pathways. Let-7 microRNA further prevents tumor formation. No teratomas have been observed in any preclinical or clinical study.
Where MUSE Cells Come From
MUSE cells are not manufactured in a lab. They already exist inside you.
They reside naturally in bone marrow, peripheral blood, adipose (fat) tissue, skin, and connective tissue throughout the body. They represent a small but significant subpopulation within mesenchymal stem cells (MSCs), accounting for roughly 1–3% of cultured MSC populations and approximately 0.01–0.03% of bone marrow mononucleated cells.
Under normal conditions, MUSE cells are continuously mobilized from the bone marrow into peripheral blood, circulating to various organs to support maintenance and repair. This mobilization rate fluctuates based on the individual’s physical condition — and it increases dramatically in response to injury.
Studies have shown that in patients who suffer a stroke or heart attack, circulating MUSE cell counts spike within 24 hours of onset, then return to baseline within 2–3 weeks. This isn’t a synthetic therapy being forced on the body. It’s a natural repair system being amplified.
How MUSE Cells Work
A four-step therapeutic mechanism that is elegant in its simplicity — and unlike anything else in stem cell science.
Damage Detection
When tissue is injured, damaged cells release sphingosine-1-phosphate (S1P) — a universal distress signal. MUSE cells detect this through their S1PR2 receptors and actively migrate toward the site of damage, bypassing the lung-trapping problem that limits conventional MSCs.
Cell Cleanup
Once at the injury site, MUSE cells engulf (phagocytose) damaged and dying cells — a macrophage-like behavior unique to MUSE cells among stem cell populations. This clears cellular debris while simultaneously triggering differentiation.
Spontaneous Differentiation
After engulfing damaged cells, MUSE cells spontaneously become the same cell type as the cells they consumed. In a damaged heart, they become cardiac cells. In a brain infarct, they become neurons. No genetic programming required.
Tissue Rebuild
The newly differentiated cells integrate into existing tissue architecture, replacing damaged cells with healthy, functional ones. This is structural regeneration — the actual rebuilding of tissue at the cellular level, not just a temporary signal.
Why This Matters: Standard MSCs work primarily through paracrine signaling — secreting helpful molecules nearby. MUSE cells go further: they actively home to damage, consume dying cells, and physically replace them with new, functional tissue. Research has confirmed this across heart, brain, liver, kidney, skin, and spinal cord.
MUSE Cells vs. Other Stem Cells
To understand why MUSE cells matter, it helps to understand the limitations of what came before them.
| Feature | Embryonic (ESCs) | iPSCs | MSCs | MUSE Cells |
|---|---|---|---|---|
| Pluripotent | ✓ Yes | ✓ Yes | ✗ Multipotent only | ✓ Yes — naturally |
| Tumor Risk | High — teratomas | Elevated | Low | None observed |
| Genetic Manipulation | Not needed | Required | Not needed | Not needed |
| Immune Rejection | Requires immunosuppression | Possible | Low | ~90% HLA-G expression |
| Active Homing | ✗ No | ✗ No | ✗ Trapped in lungs | ✓ S1P-driven |
| Direct Tissue Rebuild | Possible | Possible | ✗ Paracrine only | ✓ Confirmed |
| Ethical Concerns | Yes — embryo-derived | No | No | No |
| Donor Use (No Matching) | ✗ | ✗ | ✓ | ✓ HLA-G tolerant |
What Makes MUSE Cells Unique
Interested in MUSE Cell Therapy?
The Stem Cell Club now offers MUSE cell treatments in St. George, Utah. Schedule a free consultation to learn if you’re a candidate.
Schedule Free ConsultationWhat the Research Shows
Over 85 peer-reviewed studies, 120+ published papers, and multiple completed Phase II clinical trials in human patients.
Acute Myocardial Infarction
Heart attack patients received a single IV dose of donor MUSE cells. Ejection fraction improved from ~41% to ~52% — a double-digit gain. In cardiology, even a 5% improvement is clinically meaningful.
Ischemic Stroke
Randomized, double-blind, placebo-controlled trial. IV-administered MUSE cells without HLA matching. Functional recovery was statistically significant and sustained through 52 weeks of follow-up.
Spinal Cord Injury
10 patients with recent cervical spinal cord injuries received donor MUSE cells. Safety confirmed with meaningful improvements in motor function, daily activities, and quality of life.
ALS (Lou Gehrig’s Disease)
First MUSE cell trial to test multiple doses (6 IV injections). Confirmed safety of repeated administration with potential therapeutic effects in this devastating condition.
Epidermolysis Bullosa
Five patients with chronic, painful skin ulcers that had been unresponsive to other treatments received a single IV dose. Treatment improved erosion area and reduced ulcer size.
Neonatal Brain Injury
MUSE cells evaluated for neonatal hypoxic-ischemic encephalopathy — brain injury from oxygen deprivation at birth. Safety and therapeutic effects were reported.
Additional Conditions Under Investigation
Preclinical research has demonstrated MUSE cell efficacy in models of liver cirrhosis, chronic kidney disease, diabetes-related skin ulcers, pulmonary fibrosis, and intracerebral hemorrhage. The breadth of these applications reflects the fundamental nature of the MUSE cell mechanism — damage-responsive, pluripotent repair that adapts to whatever tissue needs rebuilding.
The MUSE Cell Safety Profile
Safety is where MUSE cells fundamentally separate from other pluripotent cell types.
Low Telomerase Activity
Unlike ESCs and iPSCs with high telomerase, MUSE cells maintain low levels — eliminating uncontrolled cell proliferation risk.
Let-7 / Lin28 Profile
High Let-7 microRNA actively suppresses oncogenic pathways. Lin28 (associated with malignancy) is downregulated.
Zero Teratoma Formation
In every preclinical study with immunodeficient mice — the gold standard test — no tumors formed. Replicated across multiple labs.
Chromosomal Stability
Maintains normal chromosomal profile even after extended culture and expansion — a critical clinical-grade requirement.
Bone Marrow Precedent
MUSE cells have been inadvertently administered in standard bone marrow transplants since 1958 — with no associated adverse effects.
Clean Trial Record
Across all completed clinical trials — heart, stroke, ALS, skin, spine, neonatal — no serious adverse events related to treatment.
The Discovery: Professor Mari Dezawa
Professor Mari Dezawa graduated from Chiba University School of Medicine in 1989, earned her PhD in 1995, and spent years studying adult stem cell biology and neural regeneration. At Kyoto University, she developed methods to induce mesenchymal stem cells to form neural and skeletal muscle cells — groundbreaking work that laid the foundation for what came next.
In 2010, working at Tohoku University, Professor Dezawa’s team identified a unique subpopulation of cells within MSC cultures that could survive extreme stress conditions — hypoxia, serum deprivation, prolonged protease exposure — that killed other stem cells. These stress-resilient survivors turned out to be naturally pluripotent, capable of generating all three germ layers from a single cell.
She named them Multilineage-differentiating Stress-Enduring cells.
What followed was over a decade of rigorous preclinical research published in journals including Proceedings of the National Academy of Sciences, Circulation Research, Journal of the American Society of Nephrology, and Stem Cells Translational Medicine.
How MUSE Cell Therapy Is Administered
One of the practical advantages of MUSE cell therapy is its simplicity.
Collection
MUSE cells are isolated from donor mesenchymal stem cells using SSEA-3 sorting via advanced laboratory techniques (FACS or MACS).
Expansion
Isolated cells are cultured and expanded to clinical scale under GMP (Good Manufacturing Practice) conditions.
Intravenous Administration
Cells are administered via standard IV infusion. No surgical implantation. No pre-differentiation. No immunosuppressive drugs required. Because MUSE cells express HLA-G, HLA matching between donor and recipient is not needed.
Clinical Protocol: In published trials, a standard dose of approximately 1.5 × 10⁷ cells in 15 mL was thawed, diluted in Ringer’s solution, and administered intravenously over 10–15 minutes. Donor-derived MUSE cells have been shown to survive in recipient tissue for up to 6 months without rejection.
MUSE Cells at The Stem Cell Club
The Stem Cell Club is proud to offer MUSE cell therapy alongside our premium umbilical cord MSC treatments — all at transparent, honest pricing.
At The Stem Cell Club, we’ve always believed that quality regenerative medicine should be accessible — not hidden behind inflated prices and pressure sales. Adding MUSE cell therapy to our offerings means our patients now have access to one of the most scientifically validated regenerative technologies available today.
Our approach remains the same: physician-guided care, transparent pricing, and honest conversations about what stem cell therapy can and cannot do. During your free consultation, we’ll discuss whether MUSE cells, our premium MSC therapy, or another protocol is right for your specific situation.
Important Note: MUSE cell therapy remains investigational in most jurisdictions. The clinical references on this page are based on published, peer-reviewed research. All treatments at The Stem Cell Club are administered under the supervision of Andrea Montana, MSN, APRN, our Medical Director.
Key Published Studies
A selection of foundational and clinically significant publications in MUSE cell research.
MUSE Cell Therapy FAQ
Ready to Learn More About MUSE Cell Therapy?
Schedule a free consultation with our team. We’ll discuss your situation honestly, explain the science, and help you determine if MUSE cell therapy or another protocol is right for you.
The Next Generation of Stem Cell Therapy Is Here
MUSE cells combine the regenerative power of pluripotent stem cells with a verified safety profile — backed by rigorous science, not hype. The Stem Cell Club brings this technology to you at an honest price.
Disclaimer: MUSE cell therapy remains investigational in most jurisdictions. All clinical references on this page are based on published, peer-reviewed research. This content is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Patients seeking regenerative treatment should consult with qualified healthcare providers. Stem cell therapy is not FDA-approved for treating specific diseases.